Updated on 2 September 2014
Neulapeg, to be available in Korean markets by early next year
Singapore: South Korea-based biopharmaceutical company, Green Cross declared that the Korean Ministry of Food and Drug Safety has granted market authorization for Neulapeg, a biosimilar of pegfilgrastim, used in the treatment of chemotherapy patients who have abnormally low neutrophil counts.
Neutrapenia (low neutrophil counts) is a serious and most common side effect of chemotherapy. Mr Su-Jung Kim, oncology team leader of Green Cross said that this approval would boost the company's cancer business in Korea. "This is a significant milestone for Green Cross, as Neulapeg is the first Green Cross oncology supportive care treatment product," he added.
Mr Kim mentioned that Neulapeg will be available in Korean markets early next year. He assured that Green Cross was poised to accelerate the introduction of Neulapeg into foreign markets.